Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Shares Outstanding for 4 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.55% to $50.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.9 million through Dec 2025, up 4.55% year-over-year, with the annual reading at $50.9 million for FY2025, 4.55% up from the prior year.
  • Shares Outstanding hit $50.9 million in Q4 2025 for Axsome Therapeutics, up from $50.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $50.9 million in Q4 2025 to a low of $4.8 million in Q2 2024.
  • Historically, Shares Outstanding has averaged $43.8 million across 4 years, with a median of $47.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding: plummeted 89.77% in 2024 and later surged 942.13% in 2025.
  • Year by year, Shares Outstanding stood at $43.5 million in 2022, then grew by 8.86% to $47.4 million in 2023, then increased by 2.78% to $48.7 million in 2024, then increased by 4.55% to $50.9 million in 2025.
  • Business Quant data shows Shares Outstanding for AXSM at $50.9 million in Q4 2025, $50.3 million in Q3 2025, and $49.8 million in Q2 2025.